Please login to the form below

Not currently logged in
Email:
Password:

Lartruvo

This page shows the latest Lartruvo news and features for those working in and with pharma, biotech and healthcare.

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo. Licensed for use with doxorubicin for soft tissue sarcoma patients. ... Until then, Lartruvo will be subject to an annual safety review by the CHMP.

Latest news

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Lilly snags first approval for sarcoma drug Lartruvo. Granted accelerated approval by the FDA becoming first front-line STS therapy for 40 years. ... Eli Lilly has picked up its first green light for its soft tissue sarcoma (STS) therapy Lartruvo, ending

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    Lilly closes on first approval for sarcoma drug Lartruvo. Orphan drug improved patient survival time by almost 12 months in phase II trial. ... It is thought that by binding to the receptor Lartruvo can slow down tumour growth.

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics